Healthy
Conditions
Keywords
Relative bioavailability, Modified release, Pharmacokinetics
Brief summary
An open-label study to understand the effect of different modified release and immediate release formulations on plasma PF-06865571 concentrations after single oral administration under fed conditions
Interventions
DRUGPF-06865571 Immediate release suspension
Suspension
DRUGPF-06865571 Slow release MR tablets
Modified release tablets
DRUGPF-06865571 Fast release MR tablets
Modified release tablets
DRUGPF-06865571 Immediate release tablets
Immediate release tablets
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy males and female of non-childbearing potential * Age of 18-55, inclusive * Body Mass Index 17.5 to 30.5 kg/m2, inclusive * Body weight \>50 kg * Not on any prescription or non-prescription drugs within 7 days or 5 half-lives prior to first dose.
Exclusion criteria
* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). * Any condition possibly affecting drug absorption (eg, gastrectomy). * A positive urine drug test. * History of regular alcohol consumption exceeding 14 drinks/week for female subjects or 21 drinks/week for male subjects (1 drink = 5 ounces \[150 mL\] of wine or 12 ounces \[360 mL\] of beer or 1.5 ounces \[45 mL\] of hard liquor) within 6 months before screening. * Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of investigational product (whichever is longer). * Screening supine BP \>=140 mm Hg (systolic) or \>= 90 mm Hg (diastolic), following at least 5 minutes of supine rest. * Screening supine 12 lead ECG demonstrating a corrected QT (QTc) interval \>450 msec or a QRS interval \>120 msec. * Subjects with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary: * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level \>=1.25 × upper limit of normal (ULN); * Total bilirubin level \>=1.5 × ULN; subjects with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is =\<ULN. * Fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product. * Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing. * History of sensitivity to heparin or heparin induced thrombocytopenia only if heparin is used to flush any intravenous catheters in the study. * History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), or hepatitis C antibody (HCVAb). * Unwilling or unable to comply with Lifestyle Requirements in the protocol * Subjects who are investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study. * Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. * Subjects who have previously participated in prior studies with PF 06865571 as the investigational product.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma Decay Half-Life (t1/2) for PF-06865571 | 0,0.5,1,2,3,4,6,8,12,24,36,48 hours post dose in each period | Plasma Decay Half-Life (t1/2) |
| Maximum Observed Plasma Concentration (Cmax) for PF-06865571 | 0,0.5,1,2,3,4,6,8,12,24,36,48 hours post dose in each period | — |
| Time to Reach Maximum Observed Concentration for PF-06865571 | 0,0.5,1,2,3,4,6,8,12,24,36,48 hours post dose in each period | Time to Reach Maximum Observed Plasma Concentration (Tmax) |
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06865571 | 0,0.5,1,2,3,4,6,8,12,24,36,48 hours post dose in each period | Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) |
| Area Under the Curve From Time Zero to Extrapolated Infinite Time for PF-06865571 | 0,0.5,1,2,3,4,6,8,12,24,36,48 hours post dose in each period | AUC (0-infinity)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-infinity). It is obtained from AUC (0-t) plus AUC (t-infinity). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with laboratory tests findings of potential clinical importance | Baseline (Day 0) up to 48 hours after last dose of study medication | Number of participants with potentially clinically important laboratory test findings |
| Number of subjects with electrocardiogram (ECG) findings of potential clinical importance | Baseline (Day 0) up to 48 hours after last dose of study medication | Number of participants with potentially clinically important ECG findings |
| Number of subjects with vital signs findings of potential clinical importance | Baseline (Day 0) up to 48 hours after last dose of study medication | Number of participants with potentially clinically important vital sign measurements |
| Number of subjects with adverse events (AEs) | Baseline up to 35 days after last dose | Number of participants with reported adverse events |
Countries
Belgium
Outcome results
None listed